3B Pharmaceuticals GmbH https://validator.w3.org/feed/docs/rss2.html Team Data privacy statement Data Privacy Statement for Job Applications Careers Imprint Impressum Erklärung zum Datenschutz Clinical Trials Request information Pipeline Chart Partnering ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors 3B Pharmaceuticals and TetraKit Technologies Announce Strategic Collaboration for Joint Radioligand Therapy (RLT) Development News 3B Pharmaceuticals Announces Option and Asset Purchase Agreement with Novartis for PSMA Radioligand Therapy Program Isotopes 3BP Assets Directions Publications RefleXion Acquires Global Rights to Radiopharmaceutical Molecule from 3B Pharmaceuticals to Treat High Unmet Need Cancers Including Brain, Pancreatic and Liver Targeted Radiotherapy Radiopharmaceuticals Publications 3B Pharmaceuticals enters into a Global Exclusive Licensing Agreement for its FAP-Targeting Peptide Technology 3BP company statement re recent events involving Clovis Oncology and FAP-2286 PurAffin Chromatography 3B Pharmaceuticals hosts industry symposium on radiopharmaceutical innovation alliances and supports the 6th Theranostic World Congress Datenschutzerklärung Theragnostics Technology About us Contact Debiopharm expands its radiopharmaceutical footprint with an exclusive in-licensing agreement of 3B Pharmaceutical’s targeted CAIX radiotherapy Therapy Imaging Pipeline Boehringer Ingelheim and 3B Pharmaceuticals sign drug discovery collaboration 3B Pharmaceuticals and Sovicell introduce a novel service offering for plasma protein binding analysis Ipsen and 3BP announce First Patient Dosed in Phase I/II study for first-in-class radionuclide (IPN01087) Notice to job applicants regarding an ongoing recruitment scam in the U.S. KNAUER and 3B Pharmaceuticals showcase novel affinity purification process for camelid antibodies Testseite blau Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharmaceuticals Ipsen enters into a licensing agreement with 3B Pharmaceuticals to develop novel radiopharmaceuticals in oncology Bioseparation & Bioprocess Technology About Nuclear Medicine Homepage